Insulin Pump for Endocrine/Metabolic: 72.3% of denials overturned
In 83 California IMR decisions from 2002 to 2025, reviewers overturned 60 (72.3%). In the last five years: 100.0% of 8. 57 were medical-necessity disputes, 26 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 3 | 100.0% |
| 2022 | 2 | 100.0% |
| 2023 | 1 | 100.0% |
| 2025 | 2 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 16 | 75.0% | 72.3% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 4 | 0.0% | 72.3% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 3 | 33.3% | 72.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Omnipod DASH pods. The American Diabetes Association (ADA) recommends that automated insulin delivery (AID) systems be offered to all adults with type 1 diabetes. In this case, given the variability of the patient’s blood glucose and history of severe hypoglycemia, as evidenced by a recent emergency department …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:The parent of a patient has requested authorization and coverage for a Tandem Mobi external ambulatory insulin pump. Continuous subcutaneous insulin infusion therapy is indicated for patients with type 1 diabetes mellitus who require intensive insulin management. Clinical guidelines support the use of insulin pump therapy, particularly when integrated with continuous …”
“The physician reviewer found that The patient has requested authorization and coverage for Tandem X2 insulin pump and accessories. In a study comparing the metabolic control of pediatric patients with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) versus MDI, the authors noted that the patients who were treated with CSII achieved relatively good metabolic control. Another study …”
And one the reviewer upheld
“The patient has requested authorization and coverage for an insulin pump. Insulin pump therapy can be beneficial in patients with diabetes type 1 who are able to monitor and inject bolus insulin prior to meals. Insulin pump therapy can improve the rates of nocturnal hypoglycemia, whereas multiple doses of insulin or basal bolus therapy has been associated with less frequent …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Insulin Pump denials for Endocrine/Metabolic overturned?
In 83 California IMR decisions from 2002 to 2025, reviewers overturned 60 (72.3%). In the last five years: 100.0% of 8. 57 were medical-necessity disputes, 26 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.